Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells
ArticleAbstract: For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerPalabras claves:Central nervous system, Demyelination, Multiple Sclerosis, Neurodegenerative disorder, Regulatory T cellsAutores:Acosta-Medina E.F., Alexey Llópiz-Arzuaga, Alonso-Ramírez R., Cervantes-Llanos M., Falcón-Cama V., Guillén-Nieto G.E., Lagumersindez-Denis N., López-Saura P.A., Marín-Prida J., Martínez-Sánchez G., Pentón-Arias E., Pentón-Rol G., Rodríguez-Jiménez E., Valenzuela-Silva C.M.Fuentes:googlescopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopus